Treating hypoparathyroidism with recombinant human parathyroid hormone (1-34): long-term safety concerns. Goujard, Cécile; Salenave, Sylvie; Briot, Karine; Chanson, Philippe; Grimon, Gilles; Kamenický, Peter. Lancet (London, England). 2020; 395: p.1304. doi:10.1016/S0140-6736(20)30538-9Article
Épidémiologie clinique